-
1
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
2
-
-
33746811910
-
Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group
-
Bijker N., Meijnen P., Peterse J.L., Bogaerts J., Van Hoorebeeck I., Julien J.P., et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. JClin Oncol 2006, 24:3381-3387.
-
(2006)
JClin Oncol
, vol.24
, pp. 3381-3387
-
-
Bijker, N.1
Meijnen, P.2
Peterse, J.L.3
Bogaerts, J.4
Van Hoorebeeck, I.5
Julien, J.P.6
-
3
-
-
0034883290
-
Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and bowel project experience
-
Fisher B., Land S., Mamounas E., Dignam J., Fisher E.R., Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and bowel project experience. Semin Oncol 2001, 28:400-418.
-
(2001)
Semin Oncol
, vol.28
, pp. 400-418
-
-
Fisher, B.1
Land, S.2
Mamounas, E.3
Dignam, J.4
Fisher, E.R.5
Wolmark, N.6
-
4
-
-
0031941704
-
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17
-
Fisher B., Dignam J., Wolmark N., Mamounas E., Costantino J., Poller W., et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-17. JClin Oncol 1998, 16:441-452.
-
(1998)
JClin Oncol
, vol.16
, pp. 441-452
-
-
Fisher, B.1
Dignam, J.2
Wolmark, N.3
Mamounas, E.4
Costantino, J.5
Poller, W.6
-
5
-
-
79952845819
-
Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS
-
Wapnir I.L., Dignam J.J., Fisher B., Mamounas E.P., Anderson S.J., Julian T.B., et al. Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. JNatl Cancer Inst 2011, 103:478-488.
-
(2011)
JNatl Cancer Inst
, vol.103
, pp. 478-488
-
-
Wapnir, I.L.1
Dignam, J.J.2
Fisher, B.3
Mamounas, E.P.4
Anderson, S.J.5
Julian, T.B.6
-
6
-
-
79851509160
-
Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis
-
Wang S.Y., Shamliyan T., Virnig B.A., Kane R. Tumor characteristics as predictors of local recurrence after treatment of ductal carcinoma in situ: a meta-analysis. Breast Cancer Res Treat 2011, 127:1-14.
-
(2011)
Breast Cancer Res Treat
, vol.127
, pp. 1-14
-
-
Wang, S.Y.1
Shamliyan, T.2
Virnig, B.A.3
Kane, R.4
-
7
-
-
79954621603
-
Significance of HER2 protein examination in ductal carcinoma in situ
-
Horimoto Y., Tokuda E., Arakawa A., Kosaka T., Saito M., Kasumi F. Significance of HER2 protein examination in ductal carcinoma in situ. JSurg Res 2011, 167:e205-e210.
-
(2011)
JSurg Res
, vol.167
-
-
Horimoto, Y.1
Tokuda, E.2
Arakawa, A.3
Kosaka, T.4
Saito, M.5
Kasumi, F.6
-
8
-
-
84857915037
-
Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ
-
Halasz L.M., Sreedhara M., Chen Y.H., Bellon J.R., Punglia R.S., Wong J.S., et al. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ. Int J Radiat Oncol Biol Phys 2012, 82:e581-e586.
-
(2012)
Int J Radiat Oncol Biol Phys
, vol.82
-
-
Halasz, L.M.1
Sreedhara, M.2
Chen, Y.H.3
Bellon, J.R.4
Punglia, R.S.5
Wong, J.S.6
-
9
-
-
77952054026
-
Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis
-
Kerlikowske K., Molinaro A.M., Gauthier M.L., Berman H.K., Waldman F., Bennington J., et al. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. JNatl Cancer Inst 2010, 102:627-637.
-
(2010)
JNatl Cancer Inst
, vol.102
, pp. 627-637
-
-
Kerlikowske, K.1
Molinaro, A.M.2
Gauthier, M.L.3
Berman, H.K.4
Waldman, F.5
Bennington, J.6
-
10
-
-
0242380840
-
Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast
-
Provenzano E., Hopper J.L., Giles G.G., Marr G., Venter D.J., Armes J.E. Biological markers that predict clinical recurrence in ductal carcinoma in situ of the breast. Eur J Cancer 2003, 39:622-630.
-
(2003)
Eur J Cancer
, vol.39
, pp. 622-630
-
-
Provenzano, E.1
Hopper, J.L.2
Giles, G.G.3
Marr, G.4
Venter, D.J.5
Armes, J.E.6
-
11
-
-
84857923923
-
Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence
-
Han K., Nofech-Mozes S., Narod S., Hanna W., Vesprini D., Saskin R., et al. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence. Clin Oncol R Coll Radiol 2012, 24:183-189.
-
(2012)
Clin Oncol R Coll Radiol
, vol.24
, pp. 183-189
-
-
Han, K.1
Nofech-Mozes, S.2
Narod, S.3
Hanna, W.4
Vesprini, D.5
Saskin, R.6
-
12
-
-
84858285120
-
HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ
-
Rakovitch E., Nofech-Mozes S., Hanna W., Narod S., Thiruchelvam D., Saskin R., et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 2012, 106:1160-1165.
-
(2012)
Br J Cancer
, vol.106
, pp. 1160-1165
-
-
Rakovitch, E.1
Nofech-Mozes, S.2
Hanna, W.3
Narod, S.4
Thiruchelvam, D.5
Saskin, R.6
-
13
-
-
84872320423
-
Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database
-
Ko B.S., Noh W.C., Kang S.S., Park B.W., Kang E.Y., Paik N.S., et al. Changing patterns in the clinical characteristics of Korean breast cancer from 1996-2010 using an online nationwide breast cancer database. JBreast Cancer 2012, 15:393-400.
-
(2012)
JBreast Cancer
, vol.15
, pp. 393-400
-
-
Ko, B.S.1
Noh, W.C.2
Kang, S.S.3
Park, B.W.4
Kang, E.Y.5
Paik, N.S.6
-
14
-
-
33750584030
-
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
-
Wen X.F., Yang G., Mao W., Thornton A., Liu J., Bast R.C., et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006, 25:6986-6996.
-
(2006)
Oncogene
, vol.25
, pp. 6986-6996
-
-
Wen, X.F.1
Yang, G.2
Mao, W.3
Thornton, A.4
Liu, J.5
Bast, R.C.6
-
15
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. NEngl J Med 2005, 353:1659-1672.
-
(2005)
NEngl J Med
, vol.353
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
-
16
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. NEngl J Med 2005, 353:1673-1684.
-
(2005)
NEngl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, C.E.5
Davidson, N.E.6
-
17
-
-
78650711397
-
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
-
Kuerer H.M., Buzdar A.U., Mittendorf E.A., Esteva F.J., Lucci A., Vence L.M., et al. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011, 117:39-47.
-
(2011)
Cancer
, vol.117
, pp. 39-47
-
-
Kuerer, H.M.1
Buzdar, A.U.2
Mittendorf, E.A.3
Esteva, F.J.4
Lucci, A.5
Vence, L.M.6
-
18
-
-
84865182133
-
Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40)
-
von Minckwitz G., Darb-Esfahani S., Loibl S., Huober J., Tesch H., Solbach C., et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer-results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat 2012, 132:863-870.
-
(2012)
Breast Cancer Res Treat
, vol.132
, pp. 863-870
-
-
von Minckwitz, G.1
Darb-Esfahani, S.2
Loibl, S.3
Huober, J.4
Tesch, H.5
Solbach, C.6
-
19
-
-
84884135755
-
-
National Cancer Institute. NSABP B-43. A phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive DCIS resected by lumpectomy. Available from: [cited 2012 Aug 30]
-
National Cancer Institute. NSABP B-43. A phase III trial comparing trastuzumab given concurrently with radiation therapy and radiation therapy alone for women with HER-2 positive DCIS resected by lumpectomy. Available from: [cited 2012 Aug 30]. http://www.clinicaltrials.gov/ct2/show/NCT00769379.
-
-
-
|